



Product datasheet

Mouse Anti-Factor VII (MM135)

Overview

Product name	Anti-Human Factor VII
Host species	Mouse
Target species	Human
Tested applications	Suitable for: IHC-P, WB, ELISA, Immunomicroscopy, Dot blot, ICC, IHC-Fr
Immunogen	A KLH-conjugated recombinant factor VII (NovoSeven) was used for immunization.
Conjugation	Unconjugated

Properties

Form	Liquid
Storage instructions	Shipped at 4 °C. Store at -20 °C. Avoid freeze/thaw cycle. Please see notes section.
Storage buffer	Phosphate buffered saline pH 7.4, contains stabilizer and ≤0.09% sodium azide.
Purity	immunogen affinity purified
Purification notes	This product was prepared by immunoaffinity chromatography using immunogen peptide coupled to Sepharose 4B.
Conjugation notes	-
Clonality	Monoclonal
Isotype	IgG
General notes	<p>For extended storage aliquot contents and freeze at -20 °C or below. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4 °C as an undiluted liquid. Dilute only prior to immediate use.</p> <p>Our customer's feedback says the antibody worked great. If in case the antibody fails to give results then please contact our scientific support team for assistance.</p>

Applications

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end-user.

Product Usage Information:

Application Dilutions

Western Blotting	3-5 ug/ml
Immunohistochemistry (Paraffin)	5-10 ug/ml
Immunohistochemistry (Frozen)	5-10 ug/ml
Immunofluorescence	5-10 ug/ml
Flow Cytometry	5-10 ug/ml

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Background:

Factor VII (EC 3.4.21.21, blood-coagulation factor VIIa, activated blood coagulation factor VII, formerly known as proconvertin) is one of the proteins that causes blood to clot in the coagulation cascade. It is an enzyme of the serine protease class. A recombinant form of human factor VIIa (eptacog alfa [activated], NovoSeven) has U.S. Food and Drug Administration approval for uncontrolled bleeding in hemophilia patients. It is sometimes used unlicensed in severe uncontrollable bleeding, although there have been safety concerns. A biosimilar form of recombinant activated factor VII (AryoSeven) is also available, but does not play any considerable role in the market.

References:

Note: This product has originally been developed at Avicenna Research Institute, Tehran, IRAN and assigned to PADZA Company according to contract 98/15/191dated 98/01/10.